| Trial ID: | L5839 |
| Source ID: | NCT01028287
|
| Associated Drug: |
Acth
|
| Title: |
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
|
| Acronym: |
ACTH-NRDN
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathy|Nephrotic Syndrome
|
| Interventions: |
DRUG: ACTH|DRUG: ACTH
|
| Outcome Measures: |
Primary: Percentage of patients achieving less than 300 mg protein per 24 hours after 6 months of Acthar Gel., 6 months | Secondary: Percentage of patients achieving greater than 50% reduction in urinary proteinuria after 6 months of Acthar Gel., 6 months
|
| Sponsor/Collaborators: |
Sponsor: Southeast Renal Research Institute | Collaborators: Mallinckrodt
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-05
|
| Completion Date: |
2011-07
|
| Results First Posted: |
|
| Last Update Posted: |
2013-05-31
|
| Locations: |
Southeast Renal Research Institute, Chattanooga, Tennessee, 37404, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01028287
|
